Yissum - Research Development Company of the Hebrew University

Tiltan Pharma

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Investment Opportunities in Startups and Spinoffs · Israel

Summary of the technology

Anti-angiogenic drug combination.
Project ID : 26-2006-467

Yissum - Research Development Company of the Hebrew University

Description of the technology

Mechanism-Based Anti-Angiogenic Drug-Combination to Treat Cancer

Tiltan Pharma is a start up company that developed a novel treatment for cancer which is now at a phase-II clinical study in metastatic pancreatic cancer. The company has recently completed a round of investment and seeks further funding to accelerate and complete this phase-II

About the company

Tiltan Pharma Ltd, an Israeli company jointly owned by Yissum (Technology transfer Company of the Hebrew University), the entrepreneurs, Israeli investors and a Canadian corporation, is dedicated to the development and commercialization of its proprietary anti-angiogenic platform for treatment of cancer and other indications.

Our product

TL-118 is a proprietary anti-angiogenic therapy aiming to starve the tumor by cutting off its blood supply.

The product represents an innovative approach to use known molecules for this indication, thereby shorten time to market and risks of development.

A recent study conducted by an independent researcher and published in the British Journal of Cancer, showed superiority of TL-118 over current standard of care anti-angiogenic agents:http://tiltanpharma.com/var/968/3032-bjc2012322a.pdf

Development Milestones

Over 150 cancer patients were exposed to TL-118 so far with excellent safety and tolerability and good signs of efficacy.

The company was granted a US-FDA IND and a recent safety report showed the product is safe and well tolerated.

Tiltan's product, TL-118, is protected by a composition of matter patent already granted in the US, Europe, Canada, Australia, Japan, China and Israel.

The company' next milestone is the completion of its phase-II pancreatic cancer study conducted in parallel in the US and Israel.

Contact details



Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

Shmuel Ben-Sasson
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Socio-economic development models, economic aspects
  • Other (uncategorised)
  • Investment Opportunities
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.